TKL Research appoints vp of operational excellence

US CRO hires Kevin Vernarec

Kevin Vernarec has been appointed to the newly created position of vice president of operational excellence at US clinical research organisation TKL Research.

Vernarec has previously held a variety of operational roles at multinational CROs covering global project management, clinical operations, proposals, budgeting and costing, CTMS and EDC systems implementation, vendor management, process re-engineering and project planning and tracking.

Headquartered in Rochelle Park, New Jersey, TKL Research provides clinical trial management services for Phase I-IV clinical research studies, including an inpatient Phase I facility and outpatient specialised research clinics.

You may also like

Regulatory

TKL Research agrees to sell clinical trials division

TKL Research, a dermatology specialty clinical research organization (CRO), announced today that it has signed an agreement to sell its Clinical Trials Division (CTD) to QuintilesIMS.
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Manufacturing

Triple your efficiency with the new DrySyn Vortex

Boost productivity with temperature-controlled parallel reactions
Manufacturing

Five critical design elements for Pelton wheel turbine flowmeters

Titan Enterprises outlines the factors for cost-effective and reliable low-flow measurement
Research & Development

Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics

Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Subscribe now